/
•
•
Context is everything.
Detailed stories on technology startups, business and economic current affairs.
Detailed stories on technology startups, business and economic current affairs.
Mounjaro’s blockbuster debut has already sparked a seismic shift across Indian healthcare, diagnostics and pharma. A marked change in consumer behaviour looks imminent.
When Eli Lilly launched Mounjaro in India in March 2025, the company likely expected decent uptake. What it got instead was a runaway blockbuster. In just eight months, Mounjaro became the highest-selling drug in the country. In October alone, sales crossed the Rs 100 crore mark, according to sales tracking agency Pharmarack. That top slot was traditionally occupied by GlaxoSmithKline's Augmentin, a low-cost antibiotic. Now, a weight-loss treatment priced between Rs 13,000 and Rs 25,000 per month had taken its place—a fundamental shift was afoot, one we were catching just in time.
It’s not just Mounjaro. Novo Nordisk’s Ozempic, already …
The stock market has taken note of the company’s ambitious plans in the domestic market. But the path ahead is far from easy.
The hospital chain’s regional as well as insured patient focus has stood it in good stead so far. Its plans to expand could pose challenges though.
The seven-year-old health tech firm has hit a wall with its core surgery business. It is now opening up hospitals.
